Moneycontrol Bureau
Biotechnology company Biocon has planned a capital expenditure of Rs 1,200 crore over the next three years, according to a research report by Citigroup Global Markets.
The capex will be funded by operating cash flows and funds...
Karvy has initiated coverage on Arvind with a buy recommendation. The brokerage believes Arvind’s widespread presence and plans to add 15-18 percent year-on-year retail space would leverage the company’s brands.
Based on valuations, Karvy...
Foreign investors have taking money off the table spooked by the depreciating rupee as it directly affects their return on investments (RoI). However, from a medium to long-term perspective, India's long-term investment appeal is still very much...